Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during  expansion by unknown
RESEARCH Open Access
Nanochelating based nanocomplex, GFc7,
improves quality and quantity of human
mesenchymal stem cells during in vitro
expansion
Maryam Hafizi1,2, Atena Hajarizadeh1, Amir Atashi3, Somayeh Kalanaky2, Saideh Fakharzadeh2, Zahra Masoumi1,
Mohammad Hassan Nazaran2* and Masoud Soleimani3*
Abstract
Introduction: Human mesenchymal stem cells (hMSCs) have been approved for therapeutic applications. Despite
the advances in this field, in vitro approaches are still required to improve the essential indices that would pave the
way to a bright horizon for an efficient transplantation in the future. Nanotechnology could help to improve these
approaches. Studies signified the important role of iron in stem cell metabolism and efficiency of copper chelation
application for stem cell expansion
Methods: For the first time, based on novel Nanochelating technology, we design an iron containing copper
chelator nano complex, GFc7 and examined on hMSCs during in vitro expansion. In this study, the hMSCs were
isolated, characterized and expanded in vitro in two media (with or without GFc7). Then proliferation, cell viability,
cell cycle analysis, surface markers, HLADR, pluripotency genes expression, homing and antioxidative defense at
genes and protein expression were investigated. Also we analyzed the spontaneous differentiation and examined
osteogenic and lipogenic differentiation.
Results: GFc7 affected the expression of key genes, improving both the stemness and fitness of the cells in a
precise and balanced manner. We observed significant increases in cell proliferation, enhanced expression of
pluripotency genes and homing markers, improved antioxidative defense, repression of genes involved in
spontaneous differentiation and exposing the hMSCs to differentiation medium indicated that pretreatment with
GFc7 increased the quality and rate of differentiation.
Conclusions: Thus, GFc7 appears to be a potential new supplement for cell culture medium for increasing the
efficiency of transplantation.
Keywords: Expansion, GFc7, Human mesenchymal stem cells, Nanocomplex, Nanochelating technology
Introduction
Human mesenchymal stem cells (hMSCs), a subset of
the multipotent non-hematopoietic stem cells found pri-
marily within the bone marrow, have been extensively
studied in recent years due to their potential for diverse
applications in regenerative medicine [1, 2]. hMSCs have
an innate self-renewal capability that is compatible with
in vitro expansion systems, enabling maintenance and
mass production that is comparable with other stem
cells for downstream clinical applications. They can also
differentiate into multiple cell types and lineages, includ-
ing osteoblasts, cardiocytes, and neural cells. In addition,
owing to their accessibility and ease of isolation from
multiple sources, hMSCs may have a broader application
spectrum because they can be readily used for auto-graft
transplantation. The HLA-DR-negative nature of hMSCs
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increases the rate of successful transplantations, and
their immunomodulatory features qualify them for treat-
ing numerous autoimmune diseases [3–6]. All of these
features together have made hMSCs one of the best can-
didates for a multitude of cell therapy applications but
despite the efficient performance of hMSCs and their
important advantages, they did not achieve satisfactory
effects in some investigations [7, 8] and the question as
to what their effective influence is after transplantation
remains unanswered [9–11].
The success rate of hMSCs cell therapy significantly
decreases due to induced apoptosis in the transplanted
cells during the first day of transplantation [8, 12]. It is
clear from the literature that this in vitro expansion
phase causes dramatic changes in the hMSCs phenotype,
which has considerable implications for the development
of effective therapies [13].
Recently, to overcome the concomitant problems of
the existing procedures, researchers have developed di-
verse new strategies for in vitro culture. Nanotechnology-
based approaches have evolved to provide nanostructures
for improving the quantity and fitness of stem cells for
more successful in vivo transplantations [14]. Nanochelat-
ing technology is a modern field that has the capacity to
design and synthetize nano structures via a self-assembly
method [15]. In previous studies using this modern tech-
nology, Hep-c nano adjuvant and MSc1 nano-complex
were synthetized. Hep-c improved cellular immune re-
sponses against hepatitis B vaccine [16]. MSc1 nano-
complex showed therapeutic behavior in an animal model
of multiple sclerosis [17] and neuroprotective effects of
three different sizes of nanochelating based nano com-
plexes in MPP(+) induced neurotoxicity [5] were recently
reported.
For the first time, based on novel nanochelating tech-
nology, we designed and synthesized an iron containing
copper chelator nanocomplex (GFc7) via a self-assembly
method.
The important role of iron in cell metabolism is clear.
Iron is a key cofactor of vital enzymes that are involved
in cell cycle promotion [18] and hMSCs proliferation
[19], so GFc7 is loaded with iron. On the other hand,
several studies reported positive outcomes of using cop-
per chelators for expansion of cord blood hematopoietic
stem cells in vitro [20] and in transplantation (phase I/II
clinical trial) [19]. Also, an increase in the extracellular
concentration of copper modulated the ability of hMSCs
to spontaneously differentiate [20]. Based on these re-
ports, GFc7 was designed in a way that has chelating
properties with the dominant affinity for copper.
Available reports imply negative effects of oxidative
stress on hMSCs functionality [21], expansion and differ-
entiation. Oxidative stress has an important role in the
initiation and progression of diseases such as cancer and
autoimmune diseases; a huge number of hMSCs recipi-
ents have these diseases [22].
Therefore, in this study, we hypothesize that the com-
petent GFc7 structure could increase the efficiency of
hMSCs by maximizing antioxidative defense [23] (com-
mon cellular model using “H2O2” for evaluating the ef-
fect of GFc7), expression of pluripotency markers, cell
expansion without spontaneous differentiation, and suit-
able homing by promoting differentiation potential.
Materials and methods
Materials and instrumentation
GFc7 nanocomplex was synthesized by Sodour Ahrar
Shargh Company (Tehran, Iran). Minimum essential
medium (α-MEM), penicillin G (100 U/ml), streptomycin
(100 μg/ml), GlutaMAX, nonessential amino acids,
trypsin-EDTA 0.25 %, and phosphate-buffered solution
(PBS) were purchased from Gibco (Gibco-Life Technolo-
gies, Carlsbad,CA, USA). Hydrogen peroxide (H2O2), so-
dium isothiocyanate, dimethyl sulfoxide (DMSO), FeCl3,
nitric acid, acetone, methanol and formalin, Triton X-
100, beta- glycerol phosphate, NHCl, and paraformalde-
hyde were purchased from Merck (Darmstadt,
Germany). AB-human serum, propidium iodide (PI),
hydrocortisone, isobutyl methyl xanthine, indometh-
acin, Oil Red stain, Alizarin Red stain, dexamethasone,
ascorbic acid 2-phosphate, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide 99 % (MTT), p-
nitrophenyl phosphate (pNP), Ficoll, and TRIzol were
from Sigma-Aldrich (St Louis, MO, USA). IntraStain kit
(Code-Nr.K2311) and all of the antibodies were obtained
from Dako (Glostrup, Denmark) and Standard SYBR
Green PCR kit from Fermentas, St. Leon-Rot, Germany.
The list of the equipment and instruments used is as
follows: FACS Calibur (Becton Dickinson, Cockeysville,
MD, USA), absorbance micro plate readers (ELx800™;
BioTek, Winooski, VT, USA), Rotor Gene 6000 instru-
ment (Corbett, Sydney, Australia), and scanning electron
microscope VEGA-TESCAN-LMU model.
Experimental overview
Bone marrow collection was approval by Shahid
Beheshti University of Medical Sciences, Tehran, Iran
(7808) and informed consent was obtained from the pa-
tients who participated in the study. The isolation and
expansion of hMSCs was performed using the standard
protocol [5].
At hMSCs isolation day from bone marrow aspirates,
cells were isolated from part of the isolated hMSCs and
pluripotency markers and spontaneous differentiation
markers were evaluated, Fig. 1.
The remnants of the isolated cells were aliquoted in
two parts: control (without GFc7) and test cells (with
GFc7); the test cells had GFc7 nanocomplex at a
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concentration of 0.1 mg/mL in hMSCs specific medium.
(This concentration was determined based on seven days
treatment of hMSCs with different concentrations of
GFc7 and then cell proliferation assay by the MTT
method). Then, the following properties were compared
in the control and test cells after 14 days culture (see
Fig. 1):
 Cell viability
 Cell cycle analysis, surface antigen analysis
 Pluripotency markers
 Spontaneous differentiation markers
 Homing marker
 Pluripotency markers
 Spontaneous differentiation markers
After 14 days of incubation, control and test groups
were analyzed for differentiation (adipogenic and osteo-
genic) and antioxidative defense was assessed, Fig. 1.
Characterization of GFc7 nano-complex
Nanochelating technology [15] was used by the Sodour
Ahrar Shargh Company to design and synthesize a novel
multi-layered nanosphere, which has an iron donor and
copper acceptor structure. This multi-layer nanosphere,
synthesized by liquid phase reduction, is called GFc7.
Synthesis
A) Iron-chelate nanosphere preparation:
Special sized iron nanospheres were produced based
on liquid phase polymerization by using an organic
acid. The method does not need protective agents to
prevent the agglomeration of the iron-nanospheres.
Controlling the mole ratio of ferrous sulfate and
organic acid can produce special sized iron-
nanospheres. First, 1 ml of 0.5 M organic acid was
dissolved in 100 ml of H2O with stirring and heating
to 90 °C simultaneously. Afterwards, 30 ml of
2.5 mM ferrous sulfate was injected into the solution
rapidly and the reaction mixture was maintained at
the boiling point for four to seven min before it was
allowed to cool to room temperature. When the
solution was clear green, the initial iron colloid was
condensed by filtering several times to remove
unreacted materials to prevent it from agglomerating.
The iron-nanospheres can be stable for three days in
the dark at 25 °C.
B) Copper-chelator polymerization:
Fig. 1 Design and time line of the study
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The prepared iron nanospheres were immersed in
20 mL of saturated glutaric acid solution. After one
h, 8 ml ethanol was added; then the solution was
heated to 40 °C and stirred slowly for about three h
to start growth progression of glutaric acid on the
surface of the prepared iron-nanospheres. Afterward,
the solution was left to cool for 24 h to precipitate
the final GFc7 multi-layer nanospheres. Then, it was
filtered and dried at 100 °C.
Scanning electron microscopy and infrared spectra (IR)
The surface morphology of this nano-complex was char-
acterized using scanning electron microscopy (SEM) at
the Razi Metallurgical Research Center.
GFc7 functional groups were characterized by IR in the
400–4,000 cm−1 range at the University of Shahid Beheshti.
Evaluation of GFc7 toxicity
Standard tests were carried out to assess the median le-
thal dose (LD50) according to the guidelines of the
Organization for Economic Co-operation and Develop-
ment (OECD, guideline 420), in the School of Pharmacy
at Tehran University of Medical Sciences [20].
hMSC isolation and culture
Bone marrow aspirates, collected on ACD-heparin, were
used to isolate hMSCs by the Ficoll density gradient
protocol. The expansion medium included DMEM F12
supplemented with 10 % human serum, penicillin G,
streptomycin, Glutamax and nonessential amino acids.
The cells were cultured in flasks and were incubated
under a humidified atmosphere with 5 % CO2 at 37 °C.
The cells were then sorted through their surface
markers by flow cytometry analysis and their differenti-
ation to osteogenic, adipogenic lineages [5].
Real-time polymerase chain reaction analysis
Total RNA was extracted using TRIzol according to the
manufacturer’s instructions. Synthesis of cDNA was car-
ried out with M-MuLV reverse transcriptase and oligo
(dT) primers. Real-time polymerase chain reaction
(qRT-PCR) was performed using a standard SYBR Green
PCR kit protocol on a Rotor Gene 6000 instrument [24,
25]. Data were normalized to GAPDH as the endogen-
ous control gene. The relative mRNA expression levels
were calculated based on the ΔCT method. The list of
primers is shown in Table 1.
Differentiation potential
After hMSCs maintenance in media with and without
GFc7 for 14 days, cells were cultured in specific differen-
tiation (adipogenic and osteogenic) media.
Adipogenic differentiation was confirmed by Oil Red
staining analysis. For osteogenic differentiation for
indicating calcium mineralization, samples were stained
by Alizarin Red. Evaluation of ALP activity and calcium
content measurements were performed for osteogenic
differentiation. All tests were done according to standard
protocols [5, 19].
Flow cytometry analysis
In all of the following tests, cell surface, intracellular
proteins and cell viability assessment were performed by
flow cytometry analysis (FACS). Data were analyzed
using Win MDI 2.8 software, and the results were illus-
trated using histograms and dot plots [25].
Table 1 Primers for qRT-PCR genes
Genes Primer sequences
1 ALP FW, 5′- GCA CCT GCC TTA CTA ACT C −3′;
RW, 5′- AGA CAC CCA TCC CAT CTC −3′;
2 COL1 FW, 5′- TGG AGC AAG AGG CGA GAG −3′;
RW, 5′- CAC CAG CAT CAC CCT TAG C −3′;
3 CXCR4 FW, 5-′ CGC CAC CAA CAG TCA GAG −3′ ;
RW, 5′- AAC ACA ACC ACC CAC AAG TC −3′;
4 GAPDH FW, 5′- GACAAGCTTCCCGTTCTCAG-3′;
RW, 5′- GAGTCAACGGATTTGGTCGT-3′;
5 H-P53 FW, 5′- GGA GTA TTT GGA TGA CAG AAA C −3′;
RW, 5′- GAT TAC CAC TGG AGT CTT C −3′;
6 LERP FW, 5′- CAA TCT GAA TGA AAC CAA ACC TC −3′;
RW, GGC TGC TCC TAT GAT ACC TC −3′;
7 REX1 FW, 5′- CGG GAC GAG GAG TGT TAT TAC −3′;
RW, 5′- CGT GTT GCT TTG CGA CTT G −3′;
8 RUNX2 FW, 5′- GCC TTC AAG GTG GTA GCC C −3′;
RW, 5′- CGT TAC CCG CCA TGA CAG TA −3′
9 Lipoprotein
lipase
FW, 5′- CCC TAC AAA GTC TTC CAT TAC −3′;
RW, 5′- AGT TCT CCA ATA TCT ACC TCT G −3′;
10 NRF2 FW, 5′- GCG ACG GAA AGA GTA TGA G −3′;
RW, 5′- GGG CAA CCT GGG AGT AG −3′;
11 NANOG FW, 5′- GCT AAG GAC AAC ATT GAT AGA AG −3′;
RW, 5′- CTT CAT CAC CAA TTC GTA CTT G −3′;
12 Osteonectin FW: 5′: CTCGCTTCGGCAGCACACATATAC-3′,
RW: 5′- ACGCTTCACGAATTTGCGTGTC-3′.
13 Osteocalcin FW, 5-′ GCA AAG GTG CAG CCT TTG TG −3′ ;
RW, 5′- GGC TCC CAG CCA TTG ATA CAG −3′;
14 OCT-4 FW, 5′- CGC CGT ATG AGT TCT GTG −3′;
RW, 5′- GGT GAT CCT CTT CTG CTT C −3′;
15 SOX2 FW; 5′- GGA CTG AGA GAA AGA AGA GGA G −3′
RW, 5′- GAA AAT CAG GCG AAG AAT AAT-3′;
16 SOD1 FW, 5′- CGA GCA GAA GGA AAG TAA TG −3′;
RW, 5′- TGG ATA GAG GAT TAA AGT GAG G −3′;
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A)Cell surface:
A total of 1 × 105 cells was allocated into 2 ml
microtubes with 100 μl PBS. Then, they were
stained at 4 °C for 30 min with monoclonal
antibodies against the following: fluorescein
isothiocyanate conjugated human CD34, CD44,
CD90, and CD105 and PE-conjugated CD73,
CD166, and HLADR. In each test, the suitable
isotype matching the antibody was used as control
to cover nonspecific binding. Cells were fixed with
1 % paraformaldehyde in PBS.
B) Intracellular proteins:
For monoclonal antibodies against human OCT4,
sample preparation and staining procedures were
performed using the IntraStain kit (Code-Nr.K2311)
according to the manufacturer’s protocol [21].
C) Cell viability assessment
To adjust flow cytometer settings for PI, we added
staining solution with gentle mixing and incubation
for one min in the dark. PI fluorescence was
determined with a FACS [25].
MTT assay
The fallowing tests, were performed by MTT assay ac-
cording to the standard protocols [17].A) The MTT Cell
Proliferation Assay measures the cell proliferation rate.B)
Measuring cell-protection capacity against H2O2-induced
oxidative injuryIn the experimental studies, H2O2 is used
for simulating OS-induced cell death [23]. The hMSCs
were plated at a density of 1x104 cells/well in 96-well
plates in 100 μl specific medium. The cells were treated
with GFc7 (0.01 mg/mL) for 14 days and were then incu-
bated with 5 μM of H2O2 for 72 hours. For the control
group, hMSCs cells were cultured without treatment with
GFc7 or H2O2 (as negative control) and were treated sim-
ply with H2O2 for 72 hours (as positive control), after
that, MTTassay and qRT-PCR analysis were performed.
Measuring cell-protection capacity against H2O2-induced
oxidative injury
In the experimental studies, H2O2 is used for simulating
OS-induced cell death [23]. The hMSCs were plated at a
density of 1x104 cells/well in 96-well plates in 100 μl
specific medium. The cells were treated with GFc7
(0.01 mg/mL) for 14 days and were then incubated with
5 μM of H2O2 for 72 hours. For the control group,
hMSCs cells were cultured without treatment with GFc7
or H2O2 (as negative control) and were treated simply
with H2O2 for 72 hours (as positive control), after the
MTT assay and qRT-PCR analysis were performed.
Statistical analysis
Student’s t-test was used to determine whether there
was a significant difference between the groups. In order
to compare multiple groups, the analysis of variance
(ANOVA) test was applied; the difference was consid-
ered significant if the P value was lower than 0.05. All
data are shown as mean ± standard deviation (SD).
Results
GFc7 characterization
SEM images showed that the size of the GFc7 nano-
complex in the first synthesis step (iron-chelate nano-
sphere) was 18 nm (Fig. 2a) and after the progression of
the copper-chelator polymerized on the surface of the
iron-chelate nanosphere, it was approximately 85 nm
(Fig. 2b).
The IR spectrum analyses clearly demonstrated that
GFc7 was an organic structure containing carbonyl, al-
cohol, and amide groups. At 3,400 cm−1, carboxylic acid
C-H bonds could be found. At 3,000 cm−1, O-H stretch
is shown. The carboxylic acid structure appears as a
wide, broad peak spectrum between 2,000 to 3,000 cm−1
(Fig. 2c).
Toxicity reports indicated that the intraperitoneal
LD50 of this nano complex was 68.190 mg/kg for mouse
and was thus considered to have low toxicity. However,
its oral LD50 for mouse was 752.63 mg/kg, classifying it
as non-toxic.
hMSC characterization
After isolation and adherence to cell culture flasks,
hMSCs were morphologically spindle shaped. The iden-
tity of the cells was determined by confirming that the
surface markers were positive for CD 90, 73, and 105
and negative for CD 45, 34, and 117 (Fig. 3a) and their
differentiation to adipogenic lineages (Fig. 3b) and osteo-
genic lineages (Fig. 3c).
GFc7 increased proliferation with a normal cell cycle
The cells were treated with 0.1 mg/ml, 0.02 mg/ml, and
0.01 mg/ml doses of GFc7 for seven days and prolifera-
tion improved, respectively, by 3.7 ± 0.035, 3.1 ± 0.025,
and 3.2 ± 0.032-fold and by 2.9 ± 0.026-fold in the con-
trol group (Fig. 4a).
The results from the cell cycle analyses in the control
and test groups were S = 13.5, G2 = 1.5, G1 = 85 and S = 6,
G2 = 9, G1 = 85, respectively. In the control cells, however,
decreases in the G2 phase of the cell cycle analysis were
noticed (Fig. 4b).
GFc7 had no negative effects on cell viability
The percentage of cell viability between the test and
control groups was equal to 98.5 ± 1 % (Fig. 4c).
GFc7 efficiently increased hMSCs pluripotency
On day 7, the expression of NANOG, SOX2, OCT4, and
REX1 in the test hMSCs increased by 197 ± 10, 2,300 ±
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97, 61 ± 8 and 30 ± 2-fold, respectively, compared with
that of the control cells (Fig. 5a).
On day 14, the expression of NANOG, SOX2, OCT4,
and REX1 in the test cells increased respectively by 63 ±
4, 31 ± 7, 8.3 ± 1, and 1.8 ± 0.05-fold compared with the
control group (Fig. 5b).
Comparing these two groups with the cells from the
isolation day verified maintenance of pluripotency in the
Fig. 2 a SEM image of Fe-chelate nanosphere (the faces of the Fe-chelate nanospheres are smooth). b SEM image of the growth
progression of Cu-chelator polymerized on the surface of Fe-chelate nanosphere, bar = 20 nm; c IR spectrum. SEM scanning electron
microscopy, IR infrared
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treated cells. In the test cells, the expression of NANOG,
SOX2, OCT4, and REX1 increased by 218 ± 30, 8±
0.4,14 ± 1 and 6 ± 1-fold, while in the control cells, the
expression increased by 85.4 ± 10,4.6±0.3, 0.4 ± 0.03 and
0.3 ± 0.01-fold, respectively. (Fig. 5c).
The histogram graphs demonstrated that OCT4 ex-
pression increased by 30 % in the test cells relative to
the control (Fig. 5d).
GFc7 inhibited spontaneous differentiation
The main issue in cell therapy is the lack of spontaneous
differentiation of the cells during in vitro culture. In this
study, the cells were examined for the expression of
osteogenic specific genes. Relative to the cells obtained
on isolation day, the expression of osteocalcin (OCN),
osteonectin (ON), alkaline phosphatase (ALP), COLI,
and RUNX2 in the test group changed by 1 ± 0.9, 2.2 ±
0.5, 0.17 ± 0.8, 0.34 ± 0.04, and 1.27 ± 1.2-fold, respectively.
In the control group, these values increased by 1.5 ± 1.4,
5.02 ± 1, 0.2 ± 0.1, 2.94 ± 1.5, and 5.1 ± 1-fold, respective to
the cells from the isolation day (Fig. 6a). Although calcium
content was equal (Fig. 6b), GFc7 induced greater levels of
ALP in the test cells compared to the control group
(Fig. 6c).
GFc7 promoted hMSCs-specific markers
After 14 days of cell proliferation, the expression levels
of surface antigens and the mean fluorescence intensity
(MFI) of MoAb-reacted proteins [26] were analyzed in
different groups (control and test). Data are shown in
the Tables 2 and 3.
Protected hMSCs against H2O2 induced cell toxicity
In the positive control group, cell viability was 58.7 ±
2 %. In the test group, cell viability increased signifi-
cantly to 83 ± 3 %. (Fig. 7a).
Real-time PCR was used to assess nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) and superoxide dis-
mutases (SOD) gene expression at the optimum dose,
demonstrating a 3.3 ± 0.5-fold increase (Nrf2) and a 6.6
± 0.8-fold increase (SOD) in the test group relative to
the controls (Fig. 7b). Nrf2 and SOD gene expression
was 1.04 ± 0.02 and 1.3 ± 0.03 in the test group and
0.314 ± 0.02 and 0.198 ± 0.01in the control group relative
to the isolation test (Fig. 7c).
GFc7 efficiently increased markers associated with cell
homing
After 14 days of cell proliferation, under the optimal
dose of GFc7, C-X-C chemokine receptor type 4 (CXCR-
Fig. 3 a Cells expressed hMSc markers. The cells were negative for CD34, CD45, and CD 117 but were positive for CD 73, CD90, and CD105.
b The ability for lipogenic differentiation was assessed by staining with Oil Red. c The ability for osteogenesis differentiation was assessed by
staining with Alizarin (400 X magnification). hMSc mesenchymal stem cell.
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4) expression increased by 8 ± 1-fold (Fig. 8a), and its
protein level increased by 5 ± 0.5 % in comparison with
the control group (Fig. 8b). hMSCs are known to be
negative for HLADR, but as observed in the flow cytom-
etry graph, the quantity of HLADR in the control cells
was 2 %, compared with 0 % in the test groups. This re-
sult demonstrated that GFc7 preserved the suppression
of HLADR expression during treatment (Table 2). Un-
like the expression of CD106 in the control group (0 %),
the expression of CD106 in the treated cells was ap-
proximately 20 ± 1 % (Table 2).
GFc7 promoted quality and rate of hMSCs differentiation
After pretreating hMSCs with the GFc7, the cells were
put through adipogenic differentiation in specific medium.
A higher rate of differentiation in the pretreated cells,
compared against the control, was confirmed by various
tests.
The percentage of adipogenic differentiation capability
of hMSCs by Oil Red staining after five days of induc-
tion between the test and control groups was 75 ± 6 %
and 25 ± 4 %, respectively (Fig. 9a) and expression of the
adipogenic genes LERP and LPA on day 5 improved, re-
spectively, by 164 ± 20 and 90 ± 20.1-fold compared with
the control (Fig. 9b).
In the osteogenic differentiation, nodules of mineral
aggregations could be observed which were stained by
Alizarin Red S. Staining was carried out on day 10 of the
differentiation process and indicated a higher rate of dif-
ferentiation in the treated cells compared to the control.
The percentage of differentiation among the test and
control cells was 50 ± 5 % and 20 ± 4 %, respectively
(Fig. 10a).
Compared with the control in the osteogenic differen-
tiation assay the expression of OCN, ON, ALP, COLI,
and RUNX2 in test cells grew, respectively, by 13.5 ± 2,
1.5 ± 0.2, 5.7 ± 1, 2 ± 0, and 2.5 ± 0.5-fold at the fifth day
after the initiation of the differentiation process and by
0.9 ± 0.01, 0.3 ± 0.01, 1 ± 0.02, 0.1 ± 0.02 and 0.6 ± 0.1-
fold ten days after initiating the differentiation process
(Fig. 10b). Calcium content assays indicated that the Ca2+
level in the control and test cells was 0.62 ± 0.01 and 0.96 ±
0.132, respectively, after five days of osteogenic treat-
ment and 2.7 ± 0.48 and 3.5 ± 0.51 after ten days of
Fig. 4 a The MTT Cell Proliferation Assay. b FACS analysis of cell cycle parameters. c Cell viability assays by flow cytometry. (data shown with dot
plot diagram). (Isotype control is an antibody of the same isotype as a primary antibody with no relevant specificity to the target antigen and it
used as negative controls to help differentiate non-specific background signal from specific antibody signal). Data are expressed as mean ± SD.
Asterisks show significant differences with p < 0.05. hMSCs human mesenchymal stem cells, PI propidium iodide
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differentiation (Fig. 10c). ALP activity level was mea-
sured and found to be 0.142 ± 0.005 (control) and
0.163 ± 0.01 (test) after five days and 0.32 ± 0.01 and
0.34 ± 0.01 after ten days (Fig. 10d).
Discussion
Human mesenchymal stem cells are undifferentiated
cells responsible for the growth, homeostasis and repair
of many tissues [27]. Although stem cells hold great po-
tential for the treatment of many injuries and degenera-
tive diseases, several obstacles must be overcome before
their therapeutic application can be realized [28]. The
application of nanotechnology to stem cell biology
would be able to address these challenges [29].
Nanostructures are of particular interest because they
have the advantageous features of a high surface-to-
volume ratio and small size (1–100 nm) [30] and they
elicit a higher degree of biological plasticity compared
with conventional micro- or macro-structures [31]. In
the field of biomaterial development and in vivo implant
technology, the nanoscale structure and morphologic
factor of the surface have played a critical role in accel-
erating the rate of cell proliferation and enhancing tissue
acceptance with a reduced immune response [31].
Particle size is the most important and most studied
factor affecting nanoparticle toxicity. Nanoparticles that
are too small (e.g., <10 nm), cause damage. In contrast,
particles >100 nm do not possess the desired pharmaco-
logical properties for effective delivery [32].
Recently nanochelating technology [15] synthetized
and introduced novel nano complexes based on a self-
assembly method [16, 17, 33].
In the present study, Gfc7 as a novel iron containing
copper chelator efficiently and in a balanced manner in-
creased hMSCs quantity and quality characters. SEM
images showed that first we had a Fe-chelate nano-
sphere, then growth progression of Cu-chelator poly-
merized on the surface of the Fe-chelate nanosphere.
Also the SEM image showed that the size of the GFc7
nano-complex was 85 nm and the IR spectrum analyses
demonstrated that this nanocomplex was an organic
structure.
Assessing the influence of GFc7 on the pluripotency
potential of hMSCs indicated that GFc7 could signifi-
cantly increase cell proliferation and simultaneously im-
prove the expression of the pluripotency markers OCT4,
SOX2, NANOG, and REX1 at day 7 and 14 after isola-
tion compared with control cells.
The physiological role of iron in cell proliferation is a
known concept, because several important enzymes in
the cell cycle progression and DNA synthesis are iron
dependent [34]. Huang et al. evaluated the effects of
Fig. 5 a Relative expression level of pluripotency genes (NONOG, SOX2, OCT-4, and REX1) on day 7 of the test compared with control. b Relative
expression level of pluripotency genes (NONOG, SOX2, OCT-4, and REX1) on day 14 of the test compared with control. c Relative expression levels
of pluripotency genes (NONOG, SOX2, OCT-4, and REX1) in the two groups (test and control) were compared with the cells obtained on the
isolation day. d Flow cytometric analysis of Oct-4 expression. The red horizontal line shows the one-fold enrichment cut off criteria. Data are
expressed as mean ± SD; Asterisks show significant differences with p < 0.05
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Table 2 Percent of CD markers between groups
CD marker Control Test
CD73 70 % 91 %
CD90 93 % 96 %
CD105 92 % 99.5 %




HLADR Negative 2 %
Table 3 Percent of mean fluorescence intensity
GMean Control Test
CD73 16 % 27 %
CD90 37 % 22 %
CD105 26 % 23 %





Fig. 6 a Effect of GFc7 nanocomplex on spontaneous differentiation, relative expression of osteogenic differentiation genes (OCN, ON, ALP, COLI,
and RUNX2) in control and test groups were compared to the cells obtained on the isolation day. b Effect of GFc7 on spontaneous
differentiation on ALP activity of hMSCs in the control and test groups compared to the cells obtained on the isolation day. c Effect of GFc7 on
spontaneous differentiation on calcium content of hMSCs in the control and test groups compared to the cells obtained on the isolation day.
The red horizontal line shows the one-fold enrichment cut off criteria. Data are expressed as mean ± SD. Asterisks show significant differences
with p < 0.05. OCN osteocalcin, ON osteonectin, ALP alkaline phosphatase
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superparamagnetic iron oxide nanoparticles (SPIONs)
on hMSCs proliferation and reported that Ferucarbo-
tran, an ionic SPIO, increases hMSCs cell numbers and
growth [35].
On the other hand, several studies have shown the role
of copper in stem cell differentiation [20]. Peled et al.
studied the effects of copper-chloride, copper chelator
tetraethylenepentamine (TEPA) and TEPA/copper mix-
tures on short- and long-term cord blood-derived CD34
(+) cell cultures. The results showed that addition of
TEPA, TEPA/copper mixtures up to equimolar concen-
trations, and the TEPA-Cu complex to CD34(+) cultures
resulted in inhibition of differentiation and enhancement
of long-term self-renewal of CD34(+) cells which was
correlated with reduction in the cellular chelatable Cu
content [36]. Also in the study by Rodríguez et al., cop-
per supplementation diminished the proliferation rate of
MSCs, increasing their ability to differentiate into the
osteogenic and the adipogenic lineages [37].
It is notable that the expression of these pluripotency
markers in GFc7 treated cells was higher compared to
the isolation day. In the study by Choudhery et al., they
reported that advancing age negatively impacts stem cell
function and such age related alterations may be detri-
mental for successful stem cell therapies. They showed
that aged hMSCs displayed senescent features, reduced
viability and proliferation and also differentiation potential
when compared with cells isolated from young donors
[38]. So the increase of pluripotency markers in GFc7
treated cells, compared to the isolation day, suggests the
potential of this nano complex as an option for functional
improvement of older patients’ MSCs.
One of the major concerns regarding the in vitro cul-
ture of hMSCs includes their spontaneous differentiation
into lineages such as osteogenic cells [39]. Notably,
treatment with GFc7 led to a stable level of RUNX-2, an
early marker that triggers the osteogenic differentiation
cascade [40], and other osteogenic genes in comparison
Fig. 7 a hMSCs protection from H2O2-induced oxidative toxicity by GFc7nono complex. b Relative expression of antioxidant gene (Nrf2, SOD) in
test group compared to the control after exposure to H2O2. c Relative expression of antioxidant gene (Nrf2, SOD) in test and control groups after
exposure to H2O2 compared to the cells obtained on the isolation day. The red horizontal line shows the one-fold enrichment cutoff criteria. Data
are expressed as mean ± SD. Asterisks show significant differences with p < 0.05. Nrf2 nuclear factor (erythroid-derived 2)-like 2, SOD
superoxide dismutases
Fig. 8 a Relative expression of CXCR-4 for test compared with control. b Flow cytometric analysis of CXCR-4 expression protein. The red horizon-
tal line shows the one-fold enrichment cutoff criteria. Data are expressed as mean ± SD. Asterisks show significant differences with p < 0.05. The
dark filled histogram represents the isotype control; the color line histogram represents expression of CXCR4 on hMSCs. CXCR-4 C-X-C chemokine
receptor type 4
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with the cells obtained on isolation day. However, the
expression of RUNX2, ON, and COLI exhibited dra-
matic increases in the control cells, which signified the
beginning of unsuitable differentiation events at genomic
levels. Conversely, the GFc7 nano-complex induced
greater levels of ALP activity. Considering that ALP is a
stemness marker for hMSCs derived from bone marrow,
embryonic stem cells, and other sources, GFc7 treatment
could be a way to maintain stemness capacity in the test
cells [41].
Nrf2 is a transcription factor known as the master
regulator of the antioxidative stress response, which
protects the cells by upgrading antioxidative defenses
[42]. Several studies have demonstrated that Nrf2 is up-
regulated by hydrogen peroxide, hypoxia, and serum
deprivation stresses, and this is in favor of the cell viabil-
ity [43, 44]. Nrf2 acts in part by enhancing SODs, key
enzymes that reduce reactive superoxide forms [45].
GFc7 could efficiently protect hMSCs viability against
H2O2 induced oxidative stress and induce expression of
Nrf2 and SOD compared to control cells. These findings
suggest that the nano complex sufficiently promoted the
antioxidative defense by improving the expression of
these transcription factors against oxidative stress.
Adhesion molecules such as CD106 are among the
most fundamental factors in improving the migration
rate of transplanted cells from the injection site into the
damaged tissues [46] Furthermore, stem cells with in-
trinsic expression of CXCR-4 on their surfaces have been
shown to be suitable candidates in cell therapy and re-
generative medicine [47]. Considering the vital roles of
CD106 (adhesion molecules) [48] and CXCR-4 in suc-
cessful cell transplantation, the improved expression of
homing markers along with the lack of HLADR expres-
sion [49] under GFc7 treatment could promise an im-
provement in the transplantation of GFc7-treated cells
to the damaged areas [46].
The improvement of differentiation potential toward
osteogenic or adipogenic features in special differenti-
ation media was confirmed by various tests. It is notable
that fat vacuoles (in adipogenic cells) were clearly ob-
served in the cytoplasm of pretreated hMSCs merely five
days after adipogenic differentiation, while no sign of dif-
ferentiation was noticed among the controls in the same
time period. Importantly, observation of fat vacuoles
mostly happened after seven days of transferring in spe-
cific differentiation medium [50]. The expression of LPA
and LERP was also assessed, demonstrating significant
enhancements in the treated cells, compared to the
control.
The enhancement of osteogenic-specific genes was
also noticed in the treated cells five days after exposure
Fig. 9 a The ability for adipogenesis differentiation was assessed by staining with Oil Red O for lipid accumulation (400 X magnification). b
Relative expression of lipogenic-specific genes (LERP, LPA) in test compared with control. The red horizontal line shows the one-fold enrichment
cutoff criteria. Data are expressed as mean ± SD. Asterisks show significant differences with p < 0.05. LPA lysophosphatidic acid
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to osteogenic differentiation medium. It is noteworthy
that the expression of RUNX2 was followed by the pro-
motion of COLI at early stages of differentiation and
ALP and OCN at later stages [51]. This enhancement
seemed to be functional, resulting in significantly higher
ALP activity and calcium content in the test cells com-
pared with the control. CD106+ hMSCs have proven to
be more capable of differentiating into osteogenic line-
ages [51, 52]. The increase in the expression of this
protein in the treated cells was further evidence of
osteogenic differentiation promotion among these cells.
Altogether, it could be perceived that along with the
increased quality of the treated cells, the duration of
differentiation was decreased. This was a perfectly pur-
poseful improvement, as the pluripotency characteristics
of the cells were efficiently preserved in the medium
containing GFc7, and the treated cells differentiated fas-
ter and were more competent after exposure to differen-
tiation medium [50].
Conclusions
The results of our study, including:: nano scale size
10 nm < e.g., < 100 nm of GFc7; self-assembly synthesis
method; novel nanocomplex (an iron containing copper
chelator nano complex); low toxicity in vivo; concomi-
tant enhancement of four pluripotency genes; inhibition
Fig. 10 a The ability for osteogenesis differentiation was assessed by staining with Alizarin Red for calcium deposition (400 X magnification).
b Relative expression of osteogenic-specific genes (OCN, ON, ALP, COLI, and RUNX2) for test group on days 7 and 14 compared with control.
c ALP activity of hMSCs in the control and test groups during osteogenic differentiation (day 5 and 10). d Calcium content of hMSCs in the control
and test groups during osteogenic differentiation (day 5 and 10). The red horizontal line shows the one-fold enrichment cut off criteria. Data are
expressed as mean ± SD. Asterisks show significant differences with p < 0.05
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of spontaneous differentiation; improved cell prolifera-
tion along with maintaining and increasing the pluripo-
tency characteristics of hMSCs; an appropriate increase
in Nrf2 during exposure to OS; protection of hMSCs
against OS-induced damages; and promotion of the
quality of hMSCs differentiation by accelerating the dif-
ferentiation process and increasing the expression of
osteogenic- or adipogenic-associated genes.
According to our results, GFc7 with a novel structure
has simultaneously affected the apex of the cellular regu-
latory system and the lower sections.
In conclusion, this study showed that the GFc7 nano-
complex has the potential to be evaluated in comple-
mentary studies as an efficient supplement for hMSCs
expansion.
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